- Home
- TBI vs CNTX Comparison
TBI vs CNTX Comparison
Compare TBI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBI | CNTX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 132.3M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBI | CNTX |
|---|---|---|
| Price | $5.54 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | 183.4K | ★ 1.7M |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,583,772,000.00 | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $0.49 |
| 52 Week High | $8.55 | $2.00 |
Technical Indicators
Market Signals| Indicator | TBI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.06 | 68.85 |
| Support Level | $4.92 | $1.39 |
| Resistance Level | $5.34 | $1.65 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 97.06 | 62.30 |
Price Performance
Historical ComparisonAbout TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.